Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3117-3122

  Veziris, Nicolas ^a   Truffot Pernot, Chantal ^a   Aubry, Alexandra ^a   Jarlier, Vincent ^a   Lounis, Nacer ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETICS; IN VIVO STUDY; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORGAN WEIGHT; PATHOLOGY; PRIORITY JOURNAL; SPLEEN; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; FLUOROQUINOLONES; LUNG; MICE; MYCOBACTERIUM TUBERCULOSIS; ORGAN SIZE; SPLEEN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0141994724     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3117-3122.2003     Document Type: Article

References (19)

1. Alvirez-Freites, E. J., J. A. Carter, and M. H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
2. Cambau, E., W. Sougakoff, M. Besson, C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1994. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J. Infect. Dis. 170:479-483.
3. Crofton, J., P. Chaulet, and D. Maher. 1997. Guidelines for the management of drug-resistant tuberculosis. Report WHO/TB/96.210. World Health Organization, Geneva, Switzerland.
4. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, and M. C. Raviglione. 2001. Global trends in resistance to antituberculosis drugs. N. Engl. J. Med. 344:1294-1303.
5. Grosset, J., and B. Ji. 1998. Experimental chemotherapy of mycobacterial diseases, p. 51-97. In P. R. J. Gandharam and P. A. Jenkins (ed.), Mycobacteria, vol. II. Chemotherapy. Chapman & Hall, New York, N.Y.
6. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
7. Hu, Y., A. R. M. Coates, and D. A. Mitchison. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657.
8. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
9. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
10. Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
11. Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob. Agents Chemother. 41:607-610.
12. Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 45:3482-3486.
13. Mitchison, D. A. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4:796-806.
14. Miyazaki, E., M. Miyazaki, J. M. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:85-89.
15. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
16. Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 72:57-64.
17. Wada, M. 1998. The adverse reactions of anti-tuberculosis drugs and its management. Nippon Rinsho 56:3091-3095.
18. World Health Organization. 1997. Treatment of tuberculosis: guidelines for national programmes, 2nd ed. Report WHO/TB/97.220. World Health Organization, Geneva, Switzerland.
19. Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother. 46: 1875-1879.